Dexcom (NSDQ:DXCM) announced today that it launched the new Dexcom One continuous glucose monitoring (CGM) system in the United Kingdom. San Diego-based Dexcom designed the Dexcom One system as an easy-to-use, real-time CGM (rt-CGM) that it aims to make more affordable and accessible for people with diabetes in the UK. According to a news release, […]
Dexcom
Analysts say high payor coverage, increased CGM adoption bodes well for Abbott, Dexcom
Analysts have suggested that companies like Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) may benefit from expected reimbursement progress. BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen. The two experts offered insights into prescriber and patient interest in […]
Dexcom’s board approves 4-for-1 forward stock split
Dexcom (Nasdaq:DXCM) announced today that its board of directors approved a four-for-one forward split of the company’s common stock. San Diego-based Dexcom’s stock split remains contingent upon stockholder approval of a restated certificate of incorporation. Approval of that would increase the number of authorized shares of common stock from 200 million to 800 million. According […]
Ypsomed partners with CamDiab on smartphone-based automated insulin delivery
Ypsomed (SWX:YPSN) announced today that it partnered with CamDiab to collaborate on managing automated insulin delivery with a mobile app. The partnership aims to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first […]
How the hospital may become a new market for CGMs
Following a breakthrough nod for Dexcom, CGMs may become a key part of hospital care. As the early stages of the COVID-19 pandemic required action in many forms, continuous glucose monitors became an unexpected part of hospital care. The FDA issued temporary guidance in April 2020 allowing for increased remote monitoring of hospital patients to […]
Diabetes tech is off to a hot start in 2022
Diabetes tech developers have high hopes for the year ahead, some of which have already come to fruition. Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes. […]
Dexcom wins CE mark for next-gen G7 CGM, will begin European launch within weeks
Dexcom (Nasdaq:DXCM) announced today that it received CE mark approval in Europe for its G7 continuous glucose monitoring (CGM) system. The San Diego–based company has also submitted for an FDA 510(k) for G7 and awaits clearance in the U.S. Dexcom designed its next-generation CGM offering as an all-in-one wearable system. It warms up in 30 […]
Dexcom wins FDA breakthrough nod for use of its CGM in hospitals
Dexcom (NSDQ:DXCM) announced that it received FDA breakthrough device designation for the use of its CGM in a hospital setting. The FDA early in the COVID-19 pandemic issued temporary guidance allowing increased remote monitoring of hospital patients in order to limit contact with hospital staff. The guidance included continuous glucose monitors. “What started as a […]
Dexcom says data shows next-gen G7 CGM provides accurate glucose readings
Dexcom (NSDQ:DXCM) published study results that demonstrate the accuracy offered by its next-generation G7 continuous glucose meter. San Diego-based Dexcom — which expects to launch the G7 soon ahead of what President and CEO Kevin Sayer said will be a year full of activity — conducted the study in adults with either type 1 or type […]
Dexcom misses on EPS in Q4
Dexcom (NSDQ:DXCM) shares are down slightly, a day after fourth-quarter results that were mixed compared to the consensus forecast. The San Diego-based continuous glucose monitoring technology developer yesterday evening posted losses of $19.4 million, or 20¢ per share, on sales of $698.2 million for the three months ended Dec. 31, 2021, for a bottom-line slide […]
